Compare CURI & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CURI | ACHV |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 42 | N/A |
| Industry | Movies/Entertainment | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.9M | 172.0M |
| IPO Year | N/A | 2018 |
| Metric | CURI | ACHV |
|---|---|---|
| Price | $2.46 | $5.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $5.83 | ★ $14.67 |
| AVG Volume (30 Days) | 326.2K | ★ 1.9M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 10.36% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.91 | N/A |
| Revenue Next Year | $12.91 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.81 | $2.00 |
| 52 Week High | $7.15 | $6.15 |
| Indicator | CURI | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 29.55 | 61.69 |
| Support Level | N/A | $4.04 |
| Resistance Level | $3.56 | $5.90 |
| Average True Range (ATR) | 0.17 | 0.37 |
| MACD | -0.05 | 0.11 |
| Stochastic Oscillator | 15.64 | 63.45 |
CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. The firm's products and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, and Others. The majority of the revenue comes from the direct business and Content licensing. Geographically, the company generates the majority of its revenue from the United States.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.